title: Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes.
abstract: OBJECTIVE
  Sitagliptin is not associated with weight gain and has neutral effects on body weight. It is unclear whether sitagliptin treatment alters serum ghrelin levels in people with type 2 diabetes.
  
  
  METHODS
  Forty-four subjects with type 2 diabetes were randomly assigned to receive sitagliptin or medical nutrition therapy (MNT) for 12 weeks. Changes in anthropometric variables, glycemic control, insulin resistance, lipid parameters, and total ghrelin levels were evaluated at baseline and following 12 weeks of treatment.
  
  
  RESULTS
  Significant decreases in body weight and body mass index were observed over the entire study period in both treatment groups. Glycosylated hemoglobin and postprandial plasma glucose levels were statistically significant decreased in the groups receiving sitagliptin compared with baseline values (p=0.021 and p=0.021, respectively), while they were unchanged in the groups receiving MNT. There was a significant decrease in total ghrelin in the groups receiving sitagliptin (p=0.04) compared with baseline values but not in the groups receiving MNT (p=0.46) at the end of the 12 weeks.
  
  
  CONCLUSIONS
  In this study of patients with type 2 diabetes, treatment with sitagliptin was associated with a significant decrease in serum ghrelin levels. These results suggest that the neutral effect of sitagliptin on weight might be associated with the suppression of fasting serum ghrelin levels.
authors.affiliation: Department of Endocrinology and Metabolism, Uludag University Medical School, Bursa, Turkey.
authors.forename: Özen
authors.initials: Ö
authors.lastname: Öz
authors.forename: Sinem
authors.initials: S
authors.lastname: Kıyıcı
authors.forename: Canan
authors.initials: C
authors.lastname: Ersoy
authors.forename: Soner
authors.initials: S
authors.lastname: Cander
authors.forename: Hakan
authors.initials: H
authors.lastname: Yorulmaz
authors.forename: Cuma Bülent
authors.initials: CB
authors.lastname: Gül
authors.forename: Oğuz Kaan
authors.initials: OK
authors.lastname: Ünal
authors.forename: Emre
authors.initials: E
authors.lastname: Sarandol
authors.forename: Emine
authors.initials: E
authors.lastname: Kırhan
authors.forename: Deniz
authors.initials: D
authors.lastname: Sığırlı
authors.forename: Erdinç
authors.initials: E
authors.lastname: Ertürk
authors.forename: Ercan
authors.initials: E
authors.lastname: Tuncel
authors.forename: Sazi
authors.initials: S
authors.lastname: Imamoğlu
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D016009:Chi-Square Distribution; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D015536:Down-Regulation; D005260:Female; D054439:Ghrelin / Q000097:blood*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D014421:Turkey
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D054439:Ghrelin; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008055:Lipids; D011719:Pyrazines; D000068900:Sitagliptin Phosphate; D014230:Triazoles; C515349:GHRL protein, human; C517652:hemoglobin A1c protein, human